Condition: Cognitive Dysfunction · Lewy Body Disease · Synucleinopathies · Sponsor: Eli Lilly and Company
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| TrialSphere Corp | Chandler, Arizona, United States | Recruiting |
| HonorHealth Research Institute | Scottsdale, Arizona, United States | Not Yet Recruiting |
| Profound Research LLC | Carlsbad, California, United States | Not Yet Recruiting |
| Irvine Clinical Research | Irvine, California, United States | Recruiting |
| UCSD - Altman Clinical and Translational Research Institute (ACTRI) | La Jolla, California, United States | Not Yet Recruiting |
| Stanford Neuroscience Health Center | Palo Alto, California, United States | Not Yet Recruiting |
| CenExel Rocky Mountain Clinical Research | Englewood, Colorado, United States | Not Yet Recruiting |
| Ki Health Partners, LLc, dba New England Institute for Clinical Research | Stamford, Connecticut, United States | Not Yet Recruiting |
| JEM Research Institute | Atlantis, Florida, United States | Recruiting |
| VIN - Aventura | Aventura, Florida, United States | Recruiting |
| Brain Matters Research | Delray Beach, Florida, United States | Recruiting |
| Neuropsychiatric Research Center of Southwest Florida | Fort Myers, Florida, United States | Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07589595